JP4805813B2 - アリール−ヘテロ芳香族生成物、それらを含む組成物及びその使用 - Google Patents

アリール−ヘテロ芳香族生成物、それらを含む組成物及びその使用 Download PDF

Info

Publication number
JP4805813B2
JP4805813B2 JP2006508355A JP2006508355A JP4805813B2 JP 4805813 B2 JP4805813 B2 JP 4805813B2 JP 2006508355 A JP2006508355 A JP 2006508355A JP 2006508355 A JP2006508355 A JP 2006508355A JP 4805813 B2 JP4805813 B2 JP 4805813B2
Authority
JP
Japan
Prior art keywords
piperazin
phenyl
methanone
imidazol
pyrrol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2006508355A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006526596A5 (OSRAM
JP2006526596A (ja
Inventor
パトリック・マイエ
アラン・ルブラン
ファビエン・トムプソン
ジール・ティーラボースキ
Original Assignee
アベンティス・ファーマ・ソシエテ・アノニム
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0306719A external-priority patent/FR2855825B1/fr
Application filed by アベンティス・ファーマ・ソシエテ・アノニム filed Critical アベンティス・ファーマ・ソシエテ・アノニム
Publication of JP2006526596A publication Critical patent/JP2006526596A/ja
Publication of JP2006526596A5 publication Critical patent/JP2006526596A5/ja
Application granted granted Critical
Publication of JP4805813B2 publication Critical patent/JP4805813B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
JP2006508355A 2003-06-04 2004-06-03 アリール−ヘテロ芳香族生成物、それらを含む組成物及びその使用 Expired - Fee Related JP4805813B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
FR0306719A FR2855825B1 (fr) 2003-06-04 2003-06-04 Produits aryl-heteroaromatiques, compositions les contenant et utilisation
FR03/06719 2003-06-04
FR04/04889 2004-05-06
FR0404889 2004-05-06
PCT/FR2004/001379 WO2004108685A1 (fr) 2003-06-04 2004-06-03 Produits aryl-heteroaromatiques, compositions les contenant et utilisation

Publications (3)

Publication Number Publication Date
JP2006526596A JP2006526596A (ja) 2006-11-24
JP2006526596A5 JP2006526596A5 (OSRAM) 2007-07-05
JP4805813B2 true JP4805813B2 (ja) 2011-11-02

Family

ID=33512659

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006508355A Expired - Fee Related JP4805813B2 (ja) 2003-06-04 2004-06-03 アリール−ヘテロ芳香族生成物、それらを含む組成物及びその使用

Country Status (16)

Country Link
US (1) US20050014765A1 (OSRAM)
EP (1) EP1641765A1 (OSRAM)
JP (1) JP4805813B2 (OSRAM)
KR (1) KR20060006850A (OSRAM)
AR (1) AR044586A1 (OSRAM)
AU (1) AU2004245269A1 (OSRAM)
BR (1) BRPI0411001A (OSRAM)
CA (1) CA2528093A1 (OSRAM)
CL (1) CL2004001359A1 (OSRAM)
IL (1) IL172222A0 (OSRAM)
MX (1) MXPA05012929A (OSRAM)
PA (1) PA8604401A1 (OSRAM)
PE (1) PE20050226A1 (OSRAM)
TW (1) TW200510344A (OSRAM)
UY (1) UY28350A1 (OSRAM)
WO (1) WO2004108685A1 (OSRAM)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050119251A1 (en) * 2001-12-21 2005-06-02 Jian-Min Fu Nicotinamide derivatives and their use as therapeutic agents
EP2289510A1 (en) 2004-09-20 2011-03-02 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes
US20080167321A1 (en) * 2004-09-20 2008-07-10 Xenon Pharmaceuticals Inc. Pyridine Derivatives For Inhibiting Human Stearoyl-Coa-Desaturase
CN101084207A (zh) * 2004-09-20 2007-12-05 泽农医药公司 杂环衍生物及其作为硬脂酰CoA去饱和酶抑制剂的用途
JP4958786B2 (ja) 2004-09-20 2012-06-20 ゼノン・ファーマシューティカルズ・インコーポレイテッド 複素環誘導体および治療薬としてのそれらの使用
JP5149009B2 (ja) * 2004-09-20 2013-02-20 ゼノン・ファーマシューティカルズ・インコーポレイテッド ヒトステアロイル−CoAデサチュラーゼを阻害するためのピリダジン誘導体
MX2007003321A (es) * 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como agentes terapeuticos.
AU2005329423A1 (en) * 2004-09-20 2006-09-28 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
MX2007003329A (es) * 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y biciclicos y su uso como inhibidores de estearoil-coa-desaturasa (scd).
US7951805B2 (en) * 2004-09-20 2011-05-31 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
CN101208089A (zh) 2005-06-03 2008-06-25 泽农医药公司 氨基噻唑衍生物作为人硬酯酰-CoA去饱和酶抑制剂
TW200800946A (en) * 2005-08-15 2008-01-01 Astrazeneca Ab Substituted piperazines as metabotropic glutamate receptor antagonists
EP2009011A1 (en) * 2006-04-14 2008-12-31 Takeda Pharmaceutical Company Limited Nitrogen-containing heterocyclic compound
DE102006027229A1 (de) * 2006-06-09 2007-12-20 Grünenthal GmbH 1,3-Disubstituierte 4-Methyl-1H-pyrrol-2-carbonsäureamide und ihre Verwendung zur Herstellung von Arzneimitteln
US8148367B2 (en) * 2007-01-12 2012-04-03 Takeda Pharmaceutical Company Limited Renin inhibitors
US9271962B2 (en) * 2008-03-17 2016-03-01 Northeastern University Inhibitors of fatty acid amide hydrolase and monoacylglycerol lipase for modulation of cannabinoid receptors
TWI469979B (zh) 2008-12-24 2015-01-21 Bial Portela & Ca Sa 脂肪酸醯胺水解酶(faah)抑制劑、以及其藥學組成物與用途
KR101297652B1 (ko) * 2010-11-25 2013-08-19 한국과학기술연구원 항암활성을 지닌 카르보아졸계 화합물
US20140343017A1 (en) * 2012-01-25 2014-11-20 Kabushiki Kaisha Yakult Honsha Pyrrole compound
KR101689093B1 (ko) 2012-06-04 2016-12-22 액테리온 파마슈티칼 리미티드 벤즈이미다졸-프롤린 유도체
WO2014057435A1 (en) 2012-10-10 2014-04-17 Actelion Pharmaceuticals Ltd Orexin receptor antagonists which are [ortho bi (hetero )aryl]-[2-(meta bi (hetero )aryl)-pyrrolidin-1-yl]-methanone derivatives
WO2014141065A1 (en) 2013-03-12 2014-09-18 Actelion Pharmaceuticals Ltd Azetidine amide derivatives as orexin receptor antagonists
MY179605A (en) 2013-12-04 2020-11-11 Idorsia Pharmaceuticals Ltd Use of benzimidazole-proline derivatives
US12172944B2 (en) 2019-03-28 2024-12-24 Council Of Scientific & Industrial Research Process for the preparation of tapentadol and analogs thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117805A0 (en) * 1995-04-07 1996-08-04 Schering Corp Carbonyl piperazinyl and piperidinyl compounds
US5880128A (en) * 1996-05-08 1999-03-09 Schering Corporation Carbonyl piperazinyl and piperidinyl compounds
DE10035908A1 (de) * 2000-07-21 2002-03-07 Asta Medica Ag Neue Heteroaryl-Derivate und deren Verwendung als Arzneimittel
DE10035927A1 (de) * 2000-07-21 2002-03-07 Asta Medica Ag Neue Heteroaryl-Derivate und deren Verwendung als Arzneimittel
DE10035928A1 (de) * 2000-07-21 2002-03-07 Asta Medica Ag Neue Heteroaryl-Derivate und deren Verwendung als Arzneimittel
FR2815032B1 (fr) * 2000-10-10 2003-08-08 Pf Medicament Nouveaux derives d'aminophenyle piperazine ou d'amino phenyle piperide inhibiteurs de proteines prenyl transferase ainsi que leurs preparations
UA79286C2 (en) * 2002-06-29 2007-06-11 Zentaris Gmbh Arylcarbonylpipererazines and heteroarylcarbonylpiperazines and their use in the treatment of benign and malignant tumors
WO2004037248A2 (en) * 2002-10-24 2004-05-06 Carex Sa Modulation of peroxisome proliferator activated receptors activity
GB0228417D0 (en) * 2002-12-05 2003-01-08 Cancer Rec Tech Ltd Pyrazole compounds

Also Published As

Publication number Publication date
KR20060006850A (ko) 2006-01-19
TW200510344A (en) 2005-03-16
PE20050226A1 (es) 2005-05-18
US20050014765A1 (en) 2005-01-20
AR044586A1 (es) 2005-09-21
HK1093339A1 (zh) 2007-03-02
UY28350A1 (es) 2004-12-31
PA8604401A1 (es) 2004-12-16
CA2528093A1 (fr) 2004-12-16
AU2004245269A1 (en) 2004-12-16
JP2006526596A (ja) 2006-11-24
WO2004108685A1 (fr) 2004-12-16
EP1641765A1 (fr) 2006-04-05
IL172222A0 (en) 2011-08-01
CL2004001359A1 (es) 2005-05-06
BRPI0411001A (pt) 2006-07-04
MXPA05012929A (es) 2006-02-28

Similar Documents

Publication Publication Date Title
JP4805813B2 (ja) アリール−ヘテロ芳香族生成物、それらを含む組成物及びその使用
EP2785693B1 (en) Aryl dihydropyridinones and piperidinones as mgat2 inhibitors
JP5008569B2 (ja) C−fmsキナーゼのインヒビターとしての芳香族アミド
MXPA06000479A (es) Productos aril-heteroaromaticos, composiciones que los contienen y utilizacion.
JP7408819B2 (ja) イソインドリン誘導体、並びにその医薬組成物及び使用
JP2003532730A (ja) 細胞増殖抑制剤として有用な1,1−ジオキソイソチアゾリジンを持つインダゾール
MX2013008718A (es) Inhibicion de il17 e ifn-gamma para tratamiento de inflamacion autoinmune.
JP2010508288A (ja) キナーゼ阻害剤として有用なヘテロサイクリックアミド化合物
SK4882003A3 (en) Nitroso diphenylamine derivative, process for the preparation thereof, its use and pharmaceutical composition containing same
JP3521214B2 (ja) 4,5−ジヒドロイソオキサゾリルアルキルピペラジン誘導体とその製造方法並びにドーパミン拮抗剤
JP2006527769A (ja) Cb1モジュレーターとしての2,3位置換5,6−ジアリール−ピラジン誘導体
US20050130989A1 (en) N-arylheteroaromatic products compositions containing them and use thereof
US5254548A (en) Compounds having an aryltriazine structure
EP3154944A2 (en) Substituted pyridinones as mgat2 inhibitors
CN100427472C (zh) 芳基-杂芳族化合物、含有它们的组合物及其用途
EP3191486A1 (en) Thioether triazolopyridine and triazolopyrmidine inhibitors of myeloperoxidase
JP3916092B2 (ja) イミダゾリジノン誘導体とその酸付加塩及び老年性痴呆症の治療薬
WO2018005336A1 (en) Macrocyclic inhibitors of myeloperoxidase
US5498720A (en) Certain triazole compounds and their pharmaceutical uses
JPH07330777A (ja) チエノ[3,2−d]ピリミジン−4−オン誘導体
CN117242061A (zh) 用于治疗艰难梭菌的二氮杂卓衍生物
WO2017040450A1 (en) Triazolopyridine inhibitors of myeloperoxidase
JPH06507387A (ja) 新規な尿素およびチオ尿素類、その製造と治療への応用
JPS5916876A (ja) カルシウムに拮抗する塩基性エステル、その製造法およびそれを有効成分とする医薬
HK1093339B (en) Aryl-heteroaromatic products, compositions containing same and use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070517

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070517

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20100630

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100720

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101015

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101022

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110120

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110301

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110523

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110719

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110811

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140819

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees